Navigation Links
Doxil in Medical News

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

...e FDA. About DOXIL(R) ( ) doxil is indicated for the treatment of patients with ov...d or recurred after prior platinum-based therapy. doxil in combination with VELCADE(R) (bortezomib) is ind...ADE and have received at least one prior therapy. doxil is also indicated for the treatment of AIDS-relate...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

... Myeloma II-5 Velcade(R) (Bortezomib) II-5 Thalomid(R) (Thalidomide) II-5 Revlimid(R) (Lenalidomide) II-6 Alkeran (Melphalan) II-6 doxil (Liposomal Doxorubicin) II-6 Trisenox(R) (Arsenic trioxide) II-6 Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons ...

Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results

...on, the Company submitted two New Drug Applications to the FDA: trabectedin (known as YONDELIS outside the U.S.) when administered in combination with doxil for the treatment of women with relapsed ovarian cancer and carisbamate, a new investigational compound for the adjunctive treatment of partial onset ...

Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer

...cer (ROC). If approved, trabectedin combined with doxil will provide a new, non-platinum treatment option ... ROC, comparing the combination of trabectedin and doxil to doxil alone in 672 patients. The study showed that pati...

Johnson & Johnson Reports 2008 Third-Quarter Results:

... patients undergoing hip or knee replacement surgery. The Company also submitted a supplemental new drug application to the FDA for the combination of doxil and Taxotere(R) for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. In July, the FDA granted pedia...

Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients

...gestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Velcade(R) Plus Doxil(R) Improves Previously Treated Multiple Myeloma Patients

...de effects such as neuropathy with the addition of doxil to the VELCADE. The findings were presented at the...idence that VELCADE increases the effectiveness of doxil against cancer cells and doxil does the same for VELCADE. "'Improved surv...
Doxil in Medical Technology

Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said that d...

Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells

...eligible will be treated with Doxil(R) (pegylated liposomal doxorubicin), an approved drug used to treat ovarian cancer, or with EC145, which combines doxil with folate (vitamin B-9). The PRECEDENT study is yet another example of CTCA's commitment to expanding medical treatment options for women bat...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... The study found that patients treated with the doxil and docetaxel combination had a 35% risk reduction...tudy. "The study suggests that the combination of doxil and docetaxel may be an effective treatment for pa...e randomly assigned to one of two treatment arms: doxil 30 mg/m2 followed by docetaxel 60 mg/m2 on the fir...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

...percent prior to transplant and 72 percent post-transplant -- VELCADE, doxil and dexamethasone (PAD or VcDD) prior to transplant showed a CR rate of...6 evaluable patients who received VELCADE at 1.3 mg/m2 on days 1, 4, 8, 11, doxil at 30 mg/m2 on day 4 and dexamethasone at 40 mg on days 1 through 4, 8 thro...

Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...k, L. E. Fayad, J. Durand About DOXIL(R) doxil is indicated in combination with VELCADE(R) (borte...ver impairment, Substitution -- The use of doxil may lead to cardiac toxicity. Myocardial damage ma...ions -- Severe myelosuppression may occur -- doxil dosage should be reduced in patients with impaired...

Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma

...gestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

...-- Phase I/II Study of Rituxan in Combination with doxil in Patients with Relapsing or Refractory B-Cel...- Preliminary Results of a Phase II Study of HCVID doxil Alternated with Methotrexate-Cytarabine in Pat...68 [accepted as abstract only]) About DOXIL doxil in combination with VELCADE(R) (bortezomib) for In...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

...alone, the current standard of care. The VELCADE + doxil abstract was selected by the Best of the American ...e (Abstract #8002) "The combination of VELCADE + doxil is highly active, with the time to disease progres...fficacy and safety of the combination of VELCADE + doxil to VELCADE monotherapy, the standard of care in pa...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

...portant Safety Information from the U.S. label for doxil Myocardial damage may lead to congestive heart fa...f doxorubicin HCl approaches 550 mg/m2. The use of doxil may lead to cardiac toxicity. Prior use of other a...are receiving concurrent cyclophosphamide therapy. doxil should be administered to patients with a history ...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

...en in previous VELCADE clinical trials. Combination Therapy with VELCADE, doxil and Dexamethasone in Newly Diagnosed Myeloma: Updated Results of a Phase II...mg/m(2) on days 1, 4, 8 and 11 of a 21-day schedule. Patients also received doxil at 30 mg/m(2) on day 4 and dexamethasone at 40 mg on days 1 through 4 or 20...
Doxil in Biological Technology

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...n Hospital, Sutton, United Kingdom About doxil (R) (doxorubicin HCl liposome injection) doxil is indicated for the treatment of patients with ov...d or recurred after prior platinum based therapy. doxil in combination with VELCADE(R) (bortezomib) is ind...

Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Medivation Announces Senior Management Promotions

...ntal therapeutics. She joined Chiron Corporation from SEQUUS Pharmaceuticals where she was responsible for the development and accelerated approval of doxil for the treatment of ovarian cancer. Dr. Bronson began her career in drug development at Cato Research, a contract research organization. She earned a...

Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...

Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection

...ongestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus doxil study. For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department...
Other Tags
(Date:9/30/2014)... Children conceived either less than one year or more than ... at increased risk for autism, a new study suggests. ... agree that the research can,t prove that birth spacing has ... important that parents understand that the odds for autism are ... far apart," said outside expert Dr. Andrew Adesman. He is ...
(Date:9/30/2014)... Power plant standards to cut climate-changing carbon emissions ... substantial human health benefits, according to a new ... on the policy options included in the final ... prevent thousands of premature deaths and hospitalizations, and ... every year., In the new study, Health Co-benefits ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... Keystone Symposia will convene the first conference of ... Global Health Series on "The Modes of Action ... immediately following the conclusion of the Grand Challenges Meeting ... of the Keystone Symposia Global Health Series, supported by ... funded travel awards for 36 investigators from developing countries ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:'Virtual breast' could improve cancer detection 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2
(Date:9/30/2014)... 30, 2014) People who suffer from asthma may ... control their asthma besides properly taking medications and avoiding ... in the Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), asthma sufferers can learn ... The woman described in the Annals article improved her ...
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 populations ... the globe dropped 52 percent, says the 2014 ... Fund (WWF). This biodiversity loss occurs disproportionately in ... of high-income countries. , In addition to the ... point to other warning signs about the overall ...
(Date:9/29/2014)... In order to support the world,s needs ... polymers and more, new and more efficient catalytic ... of researchers, including several from Wayne State University, ... a new grant from the National Science Foundation. ... Design of Multicomponent Materials for Electrocatalytic Cascade Reactions," ...
Breaking Biology News(10 mins):Asthma symptoms kicking up? Check your exposure to air pollution 2Half of global wildlife lost, says new WWF report 2Wayne State research aims to develop new, more efficient catalytic materials 2
Other Contents